Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral CR845 in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

NCT03995212 is registered in ClinicalTrials.gov with Cara Therapeutics, Inc. as lead sponsor.

NCT NCT03995212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03995212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral CR845 in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
Lead sponsor
Cara Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 25, 2019
Completion date
June 29, 2022
Enrollment
14 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cholestatic pruritus